What can we learn from the recent blood glucose lowering megatrials?

Journal of Diabetes Investigation

Volumn 2, Issue 1, 2011, Pages 1-5

  Chan, Juliana Cn ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diabetes; Disease management; Randomized clinical trials

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIPID;

ALBUMINURIA; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; EARLY INTERVENTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE SYSTEM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY;

EID: 79956227448     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00063.x     Document Type: Short Survey

References (44)

1. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21: 69-75.
3. Sprafka JM, Burke GL, Folsom AR, et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. Diabetes Care 1991; 14: 537-543.
4. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction on hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
5. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 235-259.
6. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
7. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
8. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
9. Stratton IM, Aler AI, Neil HA, et al. Association of glycemia with microvascular and macrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
10. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
11. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
12. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
13. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009; 52: 1219-1226.
14. Chew EY, Ambrosius WT, Davis MD, et al Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 233-244.
15. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187-192.
16. Woodward M, Zhang X, Barzi F, et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003; 26: 360-366.
17. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-1101.
18. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
19. Yang X, So WY, Kong AP, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 2008; 101: 596-601.
20. Morrish NJ, Wang S, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Survey of Vascular Diseases in Diabetes. Diabetologia 2001; 44: S14-S21.
21. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005; 48: 1674-1675.
22. Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063.
23. Chan JC, Wat NM, So WY, et al. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL study. Diabetes Care 2004; 27: 874-879.
24. Luk A, Chan JC. Diabetic nephropathy--what are the unmet needs? Diabetes Res Clin Pract 2008; 82(Suppl 1): S15-S20.
25. Clarke PM, Glasziou P, Patel A, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med 2010; 7: e1000236.
26. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
27. Yang X, So WY, Tong PC, et al. Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med 2008; 168: 451-457.
28. So WY, Kong AP, Ma RC, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006; 29: 2046-2052.
29. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
30. Luk AO, So WY, Ma RC, et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5, 829 patients with type 2 diabetes: A 5-year prospective analysis of the Hong Kong diabetes registry. Diabetes Care 2008; 31: 2357-2361.
31. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1121-1127.
32. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008; 24: 353-363.
33. Desouza C, Salazar H, Cheong B, et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 26: 1485-1489.
34. Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010; 26: 239-244.
35. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909.
36. Marshall SM. Intensive diabetes management for high-risk patients: how best to deliver? Diabetes Care 2009; 32: 1132-1133.
37. Chan JCN, So WY, Yeung CY, et al. The SURE study: effects of structured versus usual care on renal endpoint in type 2 diabetes: a randomized multi-centre translational study. Diabetes Care 2009; 32: 977-982.
38. Grant RW, Hamrick HE, Sullivan CM, et al. Impact of population management with direct physician feedback on care of patients with type 2 diabetes. Diabetes Care 2003; 26: 2275-2280.
39. So WY, Chan JC. The role of the multidisciplinary team. In: Goldstein DB, Cockram CS (eds). Textbook of Diabetes. Wiley-Blackwell, 2010; pp. 969-983.
40. Ko GT, So WY, Tong PC, et al. From design to implementation--the Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program. BMC Med Inform Decis Mak 2010; 10: 26.
41. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23: 579-593.
42. Funnell MM, Anderson RM. Changing office practice and health care systems to facilitate diabetes self-management. Curr Diab Rep 2003; 3: 127-133.
43. Chan JCN, Gagliardino JJ, Baik SH, et al. Multi-faceted determinants for achieving glycaemic control: The International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009; 32: 227-233.
44. UKPDS. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.